Several molecules, including those which share the same targets as approved in other indications (e.g., pertuzumab and trastuzumab emtansine target HER2, bevacizumab targets VEGFR) have shown negative results in their respective pivotal clinical trials for GC. This evidence concerns the gene KDR and gastric cancer.